METOPROLOL TARTRATE INJECTION USP SOLUTION

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

METOPROLOL TARTRATE

Beszerezhető a:

SANDOZ CANADA INCORPORATED

ATC-kód:

C07AB02

INN (nemzetközi neve):

METOPROLOL

Adagolás:

1MG

Gyógyszerészeti forma:

SOLUTION

Összetétel:

METOPROLOL TARTRATE 1MG

Az alkalmazás módja:

INTRAVENOUS

db csomag:

5ML

Recept típusa:

Prescription

Terápiás terület:

BETA-ADRENERGIC BLOCKING AGENTS

Termék összefoglaló:

Active ingredient group (AIG) number: 0111923004; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2005-09-02

Termékjellemzők

_Metoprolol Tartrate Injection USP _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
INCLUDING CONSUMER INFORMATION
PR
METOPROLOL TARTRATE INJECTION USP
(metoprolol tartrate)
5 mL vials (1 mg/mL)
β-Adrenergic Receptor Blocking Agent
Sandoz Canada Inc.
Date of Revision: August 10, 2020
110 Rue de Lauzon
Boucherville, QC, Canada
J4B 1E6
Submission Control No: 240543
_Metoprolol Tartrate Injection USP _
_ _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
10
DOSAGE AND ADMINISTRATION
.....................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
21
STORAGE AND STABILITY
.................................................................................................
25
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
25
DOSAGE FORMS, COMPOSITION AND
PACKAGING..................................................... 25
PART II: SCIENTIFIC INFORMATION
...............................................................................
26
PHARMACEUTICAL INFORMATION
.................................................................................
26
DETAILED PHARMACOLOGY
............................................................................................
27
TOXICOLOGY...........